What do many pharmaceutical companies across the world do when the number of new molecules that get past human clinical trials and the regulatory approval process is in steady decline? They cash in on drugs that manage to pass all the hurdles and milk them even after the patent expires by evergreening them, a practice that drug companies have come to master over the years. Shockingly, some pharmaceutical companies have achieved the dubious distinction of getting certain dr ugs approved by the regulatory body even when the results of clinical trials are not completely favourable. The storyline and the modus operandi remain the same; only the players involved and the products are different. This comes out from a study done by the department of psychology at the University of Hull, United Kingdom, and reported in the journal PLoS [Public Library of Science] Medicine. Analysis of data, both published and unpublished, from all the clinical trials involving more than 5,000 patients of the new-generation anti-depressants